Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
7(78%)
Results Posted
500%(5 trials)

Phase Distribution

Ph phase_2
6
67%
Ph phase_1
1
11%
Ph not_applicable
1
11%

Phase Distribution

1

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
6(75.0%)
N/ANon-phased studies
1(12.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

7

trials recruiting

Total Trials

9

all time

Status Distribution
Active(7)
Completed(1)
Terminated(1)

Detailed Status

Active, not recruiting6
Recruiting1
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
7
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (12.5%)
Phase 26 (75.0%)
N/A1 (12.5%)

Trials by Status

recruiting111%
completed111%
active_not_recruiting667%
withdrawn111%

Recent Activity

Clinical Trials (9)

Showing 9 of 9 trials
NCT07498465Phase 1

A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia

Withdrawn
NCT02465060Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Active Not Recruiting
NCT06360575Phase 2

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Active Not Recruiting
NCT06360588Phase 2

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

Active Not Recruiting
NCT06136897Phase 2

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

Active Not Recruiting
NCT06303167Phase 2

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Active Not Recruiting
NCT06357975Phase 2

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Active Not Recruiting
NCT06449755Not Applicable

Elastic Nail Versus Screw for Intramedullary Fixation of Displaced Fractures of the Fifth Metacarpal Neck

Recruiting
NCT05070000

Value of Ultrasound and Computed Tomography in the Diagnosis of Acute Appendicitis With Histopathology as Gold Standard.

Completed

All 9 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
9